An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
635 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Novartis Investigative Site
CABA, Buenos Aires, Argentina
Recruiting - Novartis Investigative Site
Caba, Buenos Aires, Argentina
Recruiting - Novartis Investigative Site
Mar del Plata, Buenos Aires, Argentina
Recruiting - Novartis Investigative Site
Mar del Plata, Buenos Aires, Argentina
Recruiting - Novartis Investigative Site
Ramos Mejía, Buenos Aires, Argentina
Recruiting - Novartis Investigative Site
CABA, Buenos Aires F.D., Argentina
Recruiting - Novartis Investigative Site
Córdoba, Córdoba Province, Argentina
Recruiting - Novartis Investigative Site
San Miguel de Tucumán, San Miguel de Tucuman, Argentina
Recruiting - Novartis Investigative Site
San Miguel de Tucumán, San Miguel de Tucuman, Argentina
Recruiting - Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Recruiting - Novartis Investigative Site
Rosario, Santa Fe Province, Argentina
Recruiting - Novartis Investigative Site
Santa Fe, Santa Fe Province, Argentina
Recruiting - Novartis Investigative Site
Buenos Aires, Argentina
Recruiting - Novartis Investigative Site
Caba, Argentina
Recruiting - Novartis Investigative Site
Capital Federal, Argentina
Recruiting - Novartis Investigative Site
Corrientes, Argentina
Recruiting - Novartis Investigative Site
Córdoba, Argentina
Active, not recruiting - Novartis Investigative Site
San Luis, Argentina
Recruiting
- Novartis Investigative Site
Camperdown, New South Wales, Australia
Recruiting - Novartis Investigative Site
Liverpool, New South Wales, Australia
Recruiting - Novartis Investigative Site
Chemside, Queensland, Australia
Recruiting - Novartis Investigative Site
Woolloongabba, Queensland, Australia
Recruiting - Novartis Investigative Site
Clayton, Victoria, Australia
Recruiting - Novartis Investigative Site
Perth, Western Australia, Australia
Recruiting
- Novartis Investigative Site
Graz, Austria
Active, not recruiting - Novartis Investigative Site
Innsbruck, Austria
Recruiting - Novartis Investigative Site
Linz, Austria
Recruiting - Novartis Investigative Site
Salzburg, Austria
Recruiting - Novartis Investigative Site
Vienna, Austria
Active, not recruiting - Novartis Investigative Site
Vienna, Austria
Recruiting
- Novartis Investigative Site
Brussels, Brussels Capital, Belgium
Recruiting - Novartis Investigative Site
Genk, Limburg, Belgium
Active, not recruiting - Novartis Investigative Site
Aalst, Oost Vlaanderen, Belgium
Recruiting - Novartis Investigative Site
Kortrijk, West-Vlaanderen, Belgium
Active, not recruiting - Novartis Investigative Site
Bruges, Belgium
Active, not recruiting - Novartis Investigative Site
Dendermonde, Belgium
Recruiting - Novartis Investigative Site
Huy, Belgium
Recruiting - Novartis Investigative Site
Mechelen, Belgium
Recruiting
- Novartis Investigative Site
Vitória, Espírito Santo, Brazil
Recruiting - Novartis Investigative Site
Salvador, Estado de Bahia, Brazil
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 11 May 2026
- Primary completion
- 9 Jan 2030
- Completion
- 9 Jan 2030
- Last update posted
- 8 Jul 2026
- Registered enrollment
- 5,700
- Registry id
- NCT07517263
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.